| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The molecular target of Oscillamide Y is not defined in the literature. As a cyanobacterial metabolite, it may have activity against certain enzymes or receptors, but specific targets have not been reported. It is a research chemical for exploratory biology.
|
|---|---|
| ln Vitro |
No quantitative in vitro activity data (IC₅0, EC₅0) are available. In a hypothetical MTT assay, the compound might exhibit cytotoxicity at high concentrations, but this is not documented. It is not a known inhibitor of common targets (kinases, GPCRs).
|
| ln Vivo |
No in vivo activity data are available. The compound has not been tested in animals for efficacy. It is not intended for therapeutic use. Researchers may screen it in phenotypic assays (e.g., anti-proliferative, antibacterial) but no data exist.
|
| Enzyme Assay |
No standard protocol exists. For analytical reference, the compound can be analyzed by reversed-phase HPLC with UV detection at 210 nm (peptide bond). A C18 column and a gradient of water/acetonitrile with 0.1% TFA are typically used. The TFA salt will affect retention.
|
| Cell Assay |
No cell-based assay data are available. If required, a cytotoxicity screen (e.g., MTT on HeLa or HEK293 cells) could be performed. The compound is typically dissolved in DMSO and tested at 0.1-100 uM. Researchers should establish their own protocols.
|
| Animal Protocol |
No animal protocol is available. For impurity qualification, standard 14-day or 28-day oral toxicity studies could be performed, but no data are published. The compound is not a drug; such studies are not expected.
|
| ADME/Pharmacokinetics |
No ADME data are available. As a cyclic peptide (MW likely >500 Da), it is expected to have low oral bioavailability and short plasma half-life. It is soluble in DMSO and, as TFA salt, may be soluble in water. Stability should be evaluated by the user.
|
| Toxicity/Toxicokinetics |
No toxicity data are available. As a research chemical, it should be handled with standard precautions. It is not known to be genotoxic. The TFA counterion is considered safe at low levels. For impurity qualification, a limit of 0.15% is typical.
|
| References | |
| Additional Infomation |
Oscillamide Y TFA is a natural product standard, typically used in natural product chemistry and metabolomics. It is stored as a lyophilized powder at -20degC. Its structure is a cyclic depsipeptide. It is not for human use.
|
| Molecular Formula |
C47H60F3N7O12
|
|---|---|
| Molecular Weight |
972.01
|
| Related CAS # |
Oscillamide Y
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0288 mL | 5.1440 mL | 10.2880 mL | |
| 5 mM | 0.2058 mL | 1.0288 mL | 2.0576 mL | |
| 10 mM | 0.1029 mL | 0.5144 mL | 1.0288 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
